News

Philadelphia, PA and College Station, TX – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, to advance the Company’s Oncology portfolio to the clinic.  Chimeron Bio selected FUJIFILM Diosynth Biotechnologies as its partner for the transfer and scale up of their drug substance manufacturing process. Drug substance manufacturing will be carried out in FUJIFILM Diosynth Biotechnologies’ state-of-the-art cGMP manufacturing facility in College Station, Texas.  Materials from this partnership will help facilitate Chimeron’s IND-enabling work and entry into the clinic.  “We selected FUJIFILM Diosynth Biotechnologies as our manufacturing partner because of their proven track record in the advanced therapies space,” said Jolly Mazumdar,

Facility acquisition includes 134 employees in manufacturing and quality positions TOKYO, April 4, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies’ global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). The 90,000 sq. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. As part of a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Atara’s promising clinical and commercial-stage

TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed. Located in Warminster, Pennsylvania, Shenandoah Biotechnology manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility. Shenandoah Biotechnology’s portfolio of recombinant proteins complements FUJIFILM Irvine Scientific, Inc.’s advanced cell culture solutions and expertise in bioprocessing, which will provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs. ENDS Notes to

Acquisition offers customers worldwide a single point of access for cGMP cell culture solutions for biopharmaceuticals, and cell and gene therapies TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, will acquire Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed. Shenandoah Biotechnology is a privately held company located in Warminster, Pennsylvania, that manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility. The use of cGMP manufactured products smooths the transition of biological therapies from preclinical to clinical phases. “At Fujifilm,

Research Triangle Park, N.C., – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, today announces a $200,000 contribution to the Wake Tech Foundation to establish the FUJIFILM Diosynth Biotechnologies Early College Suite. Located on the Wake Technical Community College’s Research Triangle Park (RTP) Campus, the suite will house the Wake Early College of Information and Biotechnologies, a partnership between the Wake County Public School System and Wake Technical Community College to provide high school students with the opportunity to earn dual-enrollment high school/college credits in IT and Biotechnology programs. In August 2022, the FUJIFILM Diosynth Biotechnologies Early College Suite will welcome an initial 150 new high school students to the campus. The Early College is expected to have annual enrollments of 75 high school students per grade level (Freshmen – Senior) at full

New licensing agreement will deliver luminescent reporter technology into iPSCs MADISON, Wis. – Promega Corporation (Promega), a leader in providing innovative solutions and technical support to the life sciences industry, and FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) technologies, today announced a strategic collaboration to advance novel assay development for drug discovery. Under a multi-year licensing agreement, FUJIFILM Cellular Dynamics will offer a wide range of custom differentiated iPSCs integrated with Promega biosensor and intracellular bioluminescent reporter capabilities for researchers and scientists to use as part of novel assay development in the drug discovery process. The strategic collaboration will merge bioluminescent reporter technology used to study cellular signaling and transcriptional activity in iPSCs, enabling researchers to create novel assays to observe cellular biology in a system that better reflects how cells behave in the human body. Cells that are differentiated

TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) announces the launch of its life sciences strategic investment fund managed by the Life Sciences Corporate Venture Capital (LS-CVC), a newly established group within the Fujifilm’s Life Sciences Strategy Headquarters in Tokyo. Fujifilm is initially investing 7B¥ (about 60 million USD ) to start the fund, targeting cutting-edge biotechnology primarily through partnerships with early-stage companies around the world. In addition to this new fund, the LS-CVC is also taking the company’s prior life science investment portfolio under management, which had been already made in the fields of regenerative medicine, cell therapeutics and drug discovery research products. Fujifilm is considering a wide range of new and innovative business constructs in order to cultivate and foster relationships with emerging biotechs to create new, and strengthen existing, businesses. In April 2021, Fujifilm established the Life Sciences Strategy Headquarters to plan and promote

TOKYO, — FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies, will operate the new site. Through this acquisition by FUJIFILM Corporation, FUJIFILM Diosynth Biotechnologies will solidify its leadership position as a complete solutions-manufacturing provider for advanced therapies. The 90,000 sq. ft. manufacturing facility is currently named “Atara T-cell Operations and Manufacturing (ATOM)” and is readily expandable to support cell therapy manufacturing processes, including allogeneic T-cell

MADISON, Wis., and SAN – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) technologies, and PhenoVista Biosciences (PhenoVista), a top provider of custom imaging-based phenotypic assay services, today announce a strategic alliance to improve the drug discovery process, by using iPSCs in screening. This alliance will enable drug discovery researchers and scientists access to services for phenotypic and High Content Screening (HCS) imaging using iPSC-derived differentiated cells, which are more biologically-relevant systems, to help in the drug discovery process. The drug discovery industry continues to leverage human-derived iPSCs for the development of assays and models to provide increased biological relevance, which can help improve the overall efficiency and success of the discovery process. iPSCs are used to create disease models, enabling researchers to understand the human biology for a range of diseases, and screen for the best possible pharmaceutical drug candidates. Additionally,

Expands the sites’ Process Development, Process Characterization and Analytical Services and adds approximately 145 skilled positions by 2024 Research Triangle Park, North Carolina — FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, today announced an expansion of its BioProcess Innovation Center (BIC) in Research Triangle Park (RTP). Through the expansion, FUJIFILM Diosynth Biotechnologies will add approximately 145 skilled positions including researchers and scientists to the RTP site by 2024. The expansion will double FUJIFILM Diosynth Biotechnologies’ capacity to support Process Characterization programs and complements the enhanced and now operational capabilities at FUJIFILM Diosynth Biotechnologies’ UK facility, announced in December 2020.  In addition, this expansion will allow FUJIFILM Diosynth Biotechnologies to better support its partners in discovering the attributes that make each protein unique and better guide clinical process development to create more robust